PAG
FATE icon

Private Advisor Group’s Fate Therapeutics FATE Stock Holding History

Private Advisor Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,481
Closed -$367K – 2155
2022
Q1 		$367K Buy
9,481
+1,938
+26% +$75K ﹤0.01% 1567
2021
Q4 		$442K Sell
7,543
-4,757
-39% -$270K ﹤0.01% 1505
2021
Q3 		$730K Buy
12,300
+6,044
+97% +$474K ﹤0.01% 1343
2021
Q2 		$543K Buy
6,256
+38
+0.6% +$3.06K ﹤0.01% 1350
2021
Q1 		$512K Buy
6,218
+95
+2% +$9.1K ﹤0.01% 1290
2020
Q4 		$557K Buy
6,123
+1,123
+22% +$69.7K 0.01% 1169
2020
Q3 		$200K Hold
5,000
– – ﹤0.01% 1405
2020
Q2 		$172K Buy
+5,000
New +$149K ﹤0.01% 1433

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Private Advisor Group's FATE Position: Q2 2022 in Review

Private Advisor Group sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 9,481 shares — an estimated $367K sold.

Private Advisor Group first reported a position in FATE in Q2 2020 and held it in 8 quarters. The position peaked at $730K in Q3 2021. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • Private Advisor Group reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Private Advisor Group sold 9,481 Fate Therapeutics shares in Q2 2022, an estimated $367K.
  • Private Advisor Group first reported a position in Fate Therapeutics in Q2 2020 and held it in 8 quarters.
  • Private Advisor Group's Fate Therapeutics position peaked at $730K in Q3 2021.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on Private Advisor Group's 13F filing for Q2 2022, filed 13 Jul 2022.